{"organizations": [], "uuid": "319de31e7986b582d5d62394f32ce1be270cd09a", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180516.html", "section_title": "Archive News &amp; Video for Wednesday, 16 May 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-novartis-says-set-to-deliver-sales/brief-novartis-says-set-to-deliver-sales-growth-margin-expansion-through-2022-idUSFWN1SN00T", "country": "US", "domain_rank": 408, "title": "BRIEF-Novartis says set to deliver sales growth, margin expansion through 2022", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.016, "site_type": "news", "published": "2018-05-16T13:25:00.000+03:00", "replies_count": 0, "uuid": "319de31e7986b582d5d62394f32ce1be270cd09a"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-novartis-says-set-to-deliver-sales/brief-novartis-says-set-to-deliver-sales-growth-margin-expansion-through-2022-idUSFWN1SN00T", "ord_in_thread": 0, "title": "BRIEF-Novartis says set to deliver sales growth, margin expansion through 2022", "locations": [], "entities": {"persons": [{"name": "brief-novartis", "sentiment": "negative"}], "locations": [{"name": "zurich", "sentiment": "none"}, {"name": "us", "sentiment": "none"}], "organizations": [{"name": "novartis ag", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "alcon", "sentiment": "none"}, {"name": "sandoz", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 16 (Reuters) - Novartis AG:\n* SAYS POSITIONED TO DELIVER SALES GROWTH AND MARGIN EXPANSION THROUGH 2022\n* SAYS ALCON RETURNING TO A POSITION OF STRENGTH AS WORLDâ€™S LEADING EYE CARE DEVICES COMPANY\n* CEO SAYS FIRM MADE MISTAKES RECENTLY AND WORLD RIGHTLY EXPECTS MORE FROM A LEADING HEALTHCARE COMPANY\n* SAYS DESPITE CONTINUING US PRICING PRESSURE, GLOBALLY, SANDOZ GROSS MARGIN IS IMPROVING\n* SAYS IN US, SANDOZ IS OPTIMIZING PORTFOLIO THROUGH TARGETED PRUNING AND LEARNING FROM RECENT SETBACKS\n* SAYS MANAGEMENT HIGHLIGHTS ACTIONS THAT HAVE RETURNED BUSINESS TO GROWTH AND IMPROVED MARGINS\n* SAYS ALCON STRATEGIC REVIEW IS ON TRACK WITH ACTION NOT EXPECTED BEFORE FIRST HALF OF 2019\n* SAYS ALCON EXPECTS TO RETURN TO LONG-TERM, SUSTAINABLE GROWTH WITH MARGINS IN LINE WITH INDUSTRY PEERS Source text for Eikon: Further company coverage: (Reporting By Zurich newsroom)\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-05-16T13:25:00.000+03:00", "crawled": "2018-05-17T14:24:25.010+03:00", "highlightTitle": ""}